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Abstract Advances in technology enable increasing amounts of data collection from individuals for
biomedical research. Such technologies, for example, in genetics and medical imaging, have also
led to important scientific discoveries about health and disease. The combination of multiple types
of high-throughput data for complex analyses, however, has been limited by analytical and logistic
resources to handle high-dimensional data sets. In our previous EU Joint Programme–
Neurodegenerative Disease Research (JPND) Working Group, called HD-READY, we developed
methods that allowed successful combination of omics data with neuroimaging. Still, several issues
remained to fully leverage high-dimensional multimodality data. For instance, high-dimensional fea-
tures, such as voxels and vertices, which are common in neuroimaging, remain difficult to harmonize.
In this Full-HDWorking Group, we focused on such harmonization of high-dimensional neuroimag-
ing phenotypes in combination with other omics data and how to make the resulting ultra-high-
dimensional data easily accessible in neurodegeneration research.
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1. Introduction
Biological data can be acquired on a large scale because
of the ongoing innovations in technical fields, giving re-
searchers the power to perform big data analyses to gain
meaningful insights in human pathophysiology [1]. Some-
times termed “omics,” this field of biomedical data analysis
incorporates various lines of research such as genomics, me-
tabolomics, proteomics, and also large-scale data sets from
medical imaging (“radiomics”). Although each of these ap-
proaches has resulted in important discoveries individually,
the integration of data from all these modalities has not yet
been fully exploited [2], in part, because the high-
dimensional nature of such analyses makes them chal-
lenging or not even feasible to perform.
In the HD-READY consortium (our previous EU Joint
Programme–Neurodegenerative Disease Research [JPND]
working group), we specifically focused on the computa-
tional and statistical requirements for analyzing high-
dimensional data, tacking several problems that require in-
frastructural capabilities far beyond that available at single
sites. Thework performed in HD-READYwas very success-
ful, resulting in two key publications of novel methods and a
software package (“HASE”) that overcame these hurdles
[3,4]. For example, associating 1.5 million neuroimaging
phenotypes with 9 million genetic variants using the
HASE software is now possible in several hours instead of
years, with great reductions in the size of data to transfer
(gigabytes instead of terabytes).
Tools delivered in HD-READYare tailor-made to tackle
challenges posed by high-dimensional data. However,
especially for large-scale imaging data sets, an important
outstanding issue is the urgent need to establish a frame-
work for harmonization. Variations in data collection and
processing pipelines complicate comparisons in neuroi-
maging studies in general, but this is especially important
in the case of high-dimensional data. For example, although
gross hippocampal volumes obtained using different
methods can still be compared to some extent, it becomes
impractical to compare a certain hippocampal voxel with
one from another data set that was acquired or processed
differently.
Laudable prior efforts from the JPND program—such as
STRIVE [5], METACOHORTS [6], and HARNESS—
aimed to harmonize, either qualitatively or quantitatively,
vascular imaging markers. These initiatives followed de-
cades of research using heterogeneous methods. Such efforts
focused primarily on aggregated neuroimaging measures,
whereas voxelwise or vertexwise harmonization remained
largely elusive. The field of high-dimensional research is
relatively young, but growing rapidly, and can greatly benefit
from such a harmonization effort early on. The Full-HD
working group was therefore set up to address two research
needs:
1. To harmonize high-dimensional neuroimaging data,
so that it can be combined with other omics data. As
a wealth of neuroimaging data have already been ac-
quired using different scanners, field strengths, and
acquisition protocols, we set out to not only define a
general framework to harmonize currently available
high-dimensional phenotypes but also determine re-
quirements for future/novel neuroimaging pheno-
types. Voxelwise and vertexwise phenotypes had a
central focus.
2. To harmonize ultra-high-dimensional neuroimaging-
by-omics data for neurodegeneration research. We
foresee these neuroimaging-by-omics data sets
becoming useful tools for neurodegeneration research.
For example, if a particular brain atrophy pattern is de-
tected in certain patients, it could be interesting to
examine whether there are genetic variants giving
rise to a similar pattern. Thus, it is essential that any
framework for harmonization of such high-
dimensional data should take the ease of use for other
researchers into account.
2. Methods
2.1. Full-HD group composition
The Full-HD working group was supported by the inter-
national Joint Programme for Neurodegenerative Diseases
initiative (www.neurodegenerationresearch.eu/). The aim
of the 2016 call was to address harmonization of neuroimag-
ing biomarkers that are relevant for neurodegenerative dis-
eases.
This working group brought together 17 experts from 5
countries, of which 4 are JPND member states (the
Netherlands, Germany, Austria, Australia; the United States
is not). Unlike the HD-READY consortium, where over 40
investigators were involved, we deliberately focused on a
key set of collaborators. These include principle investiga-
tors of some of the largest neuroimaging cohorts and consor-
tia worldwide (Study of Health In Pomerania [SHIP],
Rotterdam Study, Austrian Stroke Prevention Study
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[ASPS], Brain Imaging Genetics [BIG], ENIGMA Con-
sortium, Framingham Heart Study), giving us access to
over 25,000 magnetic resonance imaging images, which
ensured that recommendations and methods developed in
the working group could be readily tested, fine-tuned, and
applied to real data sets. Furthermore, we included not
only experts on high-dimensional neuroimaging but also ex-
perts on omics data and neurodegeneration research.
2.2. Mode of operation
Over the course of 6 months, the working group held
several teleconferences, one face-to-face meeting, and
several outreach activities to disseminate our findings.
Outreach included (1) presenting our work at scientific meet-
ings in poster and oral sessions, that is, the Alzheimer Asso-
ciation International Conference, the VasCog conference,
and the Organization for Human Brain Mapping [OHBM]
meeting; (2) contacting organizers of various teaching
courses and summer schools on statistical and imaging
methods with the request to include our methodology in their
course work, that is, Erasmus Summer Programme, Neuro-
epiomics, and the Cognomics Radboud Summer School Pro-
gramme; and (3) publishing the results and
recommendations from this working group in high-impact
journals with a focus on open access publishing.
3. Results
3.1. Full-HD methodological framework
Given the high-dimensional origin of the omics and neu-
roimaging phenotypes, we developed and integrated quality
control and harmonization methods for such data into the
HASE software [4]. This framework relies heavily on the
partial derivatives approach [3], that is, the proposed meta-
analysis algorithm (developed during HD-READY), which
allows for more insight into the data compared with classical
meta-analysis and thus also more quality control. To illus-
trate this, we show that for voxelwise analyses, it is possible
to generate mean gray matter density maps per cohort
without access to individual-level data (Fig. 1). This makes
it possible to verify that imaging processing pipelines used
were consistent between cohorts and that all brain regions
were included in the analysis. During the pilot phase of
Full-HD, we were able to detect, among other errors, incor-
rect modulation of images, incorrect masking of images,
incorrect normalization of phenotypes, and even in one
case incorrect phenotypes themselves. Most errors would
not have been detected using the quality control used in con-
ventional meta-analysis. In addition, this framework allows
for reduction of noise and false-positive errors. Specifically,
based on such mean maps, researchers can screen and if
required exclude phenotypes (e.g., voxels) that have little
variation (which may be unexpected, or possibly erroneous)
and create a mask for the phenotype analysis space (Fig. 2);
this approach has some similarities to the approach
commonly used for genetics data when filtering variants
based on their minor allele frequency [7]. Importantly, this
approach would also be applicable for quality control and
harmonization of epigenetic data, gene expression data, me-
tabolomics, and the microbiome.
3.2. Full-HD logistical framework
In the HASE software, the computational burden is
already shifted almost entirely to the meta-analysis stage,
making it possible for a small cohort at a site with modest
computational capacity to join in with multisite efforts.
Fig. 1. Graymatter density maps for three cohorts generated from the partial derivatives.Mean graymatter density maps for three cohorts (the Rotterdam Study,
SHIP, and ADNI), generated without access to individual-level data. This makes it possible to ensure that imaging processing pipelines were consistent between
cohorts and all brain regions were included in the analysis. Maps of the local variation could also be derived. Abbreviations: ADNI, Alzheimer’s Disease Neuro-
imaging Initiative; SHIP, Study of Health In Pomerania.
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For the access to the resulting ultra-high-dimensional data
sets, we recommend a similar solution with centralized stor-
age of such data, to reduce the logistic burden for individual
sites. Two approaches are put forward. First, it is possible to
store the ultra-high-dimensional data on a storage server,
which, depending on the type of analysis, would require
several terabytes. In this case, a database format such as
hdf5 [8], as used in HASE, will provide rapid access within
such huge data sets. The second approach would be not to
store the results of ultra-high-dimensional analyses but
rather the partial derivatives. These partial derivatives are
much smaller in size, but some additional computation
would be needed to obtain the final results. In this approach,
a storage server would not be sufficient but would need to be
combined with processing power for the necessary computa-
tions. An online portal providing intuitive interaction with
the data would likely be most suited for everyday researchers
and clinicians aiming to query the data [9,10]. Those who
would want to do more in-depth research with raw data
could be granted access.
The full results of these analyses are outside the scope of
the current report and will be described in a separate article.
4. Discussion
In this JPND working group, we aimed to develop a
framework for harmonizing ultra-high-dimensional imaging
genetics analyses. Key features included dealing with voxel-
wise and vertexwise neuroimaging phenotypes. Importantly,
other high-dimensional -omics technologies, such as geno-
mics, proteomics, and metabolomics, among others, are
also important for neurodegenerative disease and pose
similar challenges as neuroimaging. Therefore, the recom-
mendations and methods from this working group may be
suitable to be incorporated by researchers working with
other -omics technologies.
Exploiting these novel, ultra-high-dimensional technolo-
gies in research on neurodegenerative disease will require
these data to be easily accessible to researchers who do
not regularly work with high-dimensional data [11,12].
However, the size and nature of these data make typical
ways of sharing data (e.g., results tables or download links
to the raw data) impractical. The working group provides
concrete recommendations for such infrastructural
challenges, that is, where to store the data and how to
make it easily retrievable in a useful manner. Having each
study acquire its own computational infrastructure is not
feasible. Central computing, for example, cloud computing
or cluster computing [13], is an emerging solution but should
adhere to legal and ethical requirements [14,15]. Again, we
emphasize that recommendations from the working group
pertaining to imaging allow for translation to other -omics
technologies.
To actively follow up on the findings of the HD-READY
and Full-HD working groups, the Uncovering Neurodegen-
erative Insights Through Ethnic Diversity (UNITED) con-
sortium was initiated (see www.theunitedconsortium.com).
Although the initial JPND working groups only included a
limited number of members, the UNITED consortium
aims to broaden the collaboration to a larger scale. This
will be done by actively recruiting collaborators through vis-
ibility at international conferences and journals, while taking
a particular interest in underrepresented populations to in-
crease diversity.
4.1. Links
Framework for efficient high-dimensional association an-
alyses (HASE): https://github.com/roshchupkin/HASE/.
Description of the framework and protocol for meta-
analysis: www.imagene.nl/HASE.
Fig. 2. Selection of harmonious phenotypes for further meta-analysis. Masking of high-dimensional neuroimaging phenotypes for meta-analysis. Here, based
on themeanmaps, phenotypeswith “low frequency” (i.e., not distributed evenly) can be excluded. This is similar to the approach common for genetic datawhere
filtering of variants is performed based on the minor allele frequency. Sagittal (left), coronal (middle), and transversal (right) sections of the mean maps.
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The Uncovering Neurodegenerative Insights Through
Ethnic Diversity (UNITED) consortium: www.theunited
consortium.com.
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RESEARCH IN CONTEXT
1. Systematic review: The authors searched the litera-
ture and inquired within their networks for methods
potentially suitable for high-dimensional analyses
of omics data. Although field-specific approaches
exist to handle big data, cross-investigations between
various types of data have been limited. These
require either data reduction or infrastructure beyond
current capabilities.
2. Interpretation: Our review indicates there is a need
for a method for jointly analyzing high-
dimensional data within the omics fields.
3. Future directions: In this report, we propose a frame-
work for analyzing high-dimensional data. Still, this
is only an initial step. Future research should focus
on the interpretation of the results of such analyses
and how the results themselves can be made easily
accessible to other researchers, both inside and
outside of the omics field.
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